Method of treating and increasing quality of patients with gallbladder dyskinesia
SUBSTANCE: invention relates to medicine, namely to gastroenterology, physiotherapy, rexlexotherapy. Method includes carrying out drug therapy. Additionally, taking into account degree of expression of anxiety-depressive disorders by Hamilton scale data, antidepressant asaphen is introduced. In case of clinically expressed disorders asaphen is introduced in dose 75 mg per day, in case of subclinically expressed affective disorders - in dose 50 mg per day. Intake of asaphen is realised during 30 days. Taking into account individual peculiarities of vegetative balance state magnetic laser puncture is performed. For this purpose used is wavelength 1.3 mcm, modulated mode, frequency 2.4 Hz, magnetic-acupuncture nozzle 50 mT. Impact is carried out during 10-30 s per one biologically active point. In case of sympathicotonia point Gl 4 is sedated and points E 25, E 36, MC 6 are toned up. In case of vagotonia point Gl 4 is toned up and points E 25, E 36, MC 6 are sedated. Course includes 10-12 procedures.
EFFECT: method increases patients' life quality, reduces treatment terms, increases remission duration, reducing number of recurrences due to correction of state of day chronobiorhythms, psychoemotional sphere and vegetative balance.
2 ex, 2 tbl
The invention relates to medicine, namely to a gastroenterologist, and can be used in the treatment of dyskinesia of the gallbladder (JP).
There is a method of treating JP, consisting of drug therapy using agents that affect the tone of smooth muscles - antiholinergiceski substances, choleretic, holekinetikam, antispasmodics and prokinetics (Grigoriev PA, Yakovenko EP Diagnosis and treatment of diseases of the digestive system. - M., 2005, 463 C.). For this purpose, use, for example, teston in a dose of 200-400 mg 3 times a day for 1-3 weeks (Yakovenko EP, Grigoriev PA Chronic disease extrahepatic ways. Diagnostics and treatment. Methodological manual for doctors. - M.: Medicine, 2001. - 31 S.). There is information about the use of duspatalin (mebeverine) at a dose of 200 mg 2 times a day for 2 weeks (Cholecystitis: an algorithm for diagnosis and medical tactics. Manual for doctors. / A Handbook edited by EverEve. - Moscow. Necr MH and CF of the Russian Federation, 2006. - 64 S.).
But this therapy does not affect obeazatelino system of the patient JP, in particular, mental status, autonomic balance, daily chronobiology, does not ensure elimination of violations of the contractility of the gallbladder, no significant impact on the prolongation of the remission, reduction of recurrence, quality of life of patients. In the same lie is known, what in the regulation of motor activity biliary system involves the sympathetic and parasympathetic divisions of the autonomic nervous system (ANS) (minushkin on. / A Handbook for physicians. - M., 2006 - 28 C.)that patients JP frequently detected non-psychotic mental disorders (Raskin V.I. Peculiarities of the psychological status of patients with chronic cholecystitis / Viglasky, Auvsi // Russian journal of gastroenterology, Hepatology, Coloproctology: Annex 15. Materials of the 7th Grew. Gastroenterological Week, Moscow, 2001 - C, No. 5. - S). Most authors attribute the tendency of an individual to anxiety and fear with a predominance of the sympathetic nervous system tone (Romanov V.V. cardiovascular system specialists carrier profile in the process of continuous operation. Way // human Physiology. 1981. - V.7, №2. - S-213.), but in some cases was shown that for chronic anxiety-depressive States is characterised by the long predominance of parasympathetic tone (Nabiullina P.P. Comparative evaluation of the efficacy of tranquilizers different chemical groups at somatogennye neurosis-like disorders: author. Diss. ... candles. the honey. Sciences / Run. - Kazan, 1977. - 22 C.). State regulatory systems, psychovegetative balance largely determines the power of therapeutic measures, rate of recurrence and prognosis in JP.
Objective: to develop a method for correcting mental status, daily chronobiotic and state of autonomic balance in patients with dyskinesia of the gallbladder in the treatment process, allowing to extend periods of remission, reduce the frequency of relapses, to improve the quality of life of patients.
The technical result is achieved by the fact that patients JP after the standard survey is conducted additional evaluation of the severity of anxiety and depressive disorders, daily monitoring of heart rate variability, evaluate the contractile function of the ha and the patient's quality of life; based on the obtained additional survey results opt comprehensive treatment.
To assess the severity of anxiety and depressive disorders use questionnaires for the following test questionnaires: the Hamilton depression rating scale to determine anxiety (HARS), the Hamilton depression rating scale to determine depression (HDRS). When interpreting the data take into account the total score for all questions, which were determined by the severity of the disorders: 0-7,0 on a scale HARS and 0-8,0 points on the scale HDRS - absence of symptoms of anxiety and depression; 7,1-16,0 scale HARS and 8.1 20.0 points on a scale HDRS - subclinical expressed signs of anxiety and depression; more 16.0 points on a scale HARS and more of 20.0 points on a scale HDRS - clinically you the Agen anxiety and depression.
To assess the autonomic balance conduct daily monitoring of the heart rate variability device, for example, "Cardio Tens 01" ("Meditech", Hungary) taking into account the recommendations of the ESC/NASPE (Standards of Heart rate Variability. Circulation. Vol.93. No. 5, March 1, 1996) and subsequent cosinor-analysis (Fearow, Seaport. Chronobiology and the bases of bioenergetics. - Moscow: "Triada-X", 2000, - 488 S.).
To assess contractile function ha perform ultrasound ha with functional breakdown (trial Breakfast - 2 raw egg yolks). Contractility assessed by changes in percentage terms of the volume of ha on an empty stomach.
To assess quality of life using a questionnaire SF-36.
When assigning a course of antidepressant azafena consider the following possible variants, obtained by processing the test questionnaires:
if the patient has clinically expressed anxiety and depression azafen administered in the dose of 75 mg per day;
if the patient has subclinical expressed anxiety and depression azafen administered in the dose of 50 mg per day
When assigning course magnetothermopower consider the following possible options:
if the patient has the original sympathicotonia (RMSSD less than 15, LF/HF less than 3.5), foot reflexology, the impact of consistently seatrout point GI 4 and tone point E 25 E 36, 6 MS;
if a patient in a vegetative status of robledal vagotonic (RMSSD more than 35, LF/HF is less than 1), when magnetothermopower consistently tone up the point GI 4, and seatrout point E 25 E 36, 6 MS.
The choice of points for the correction of vegetative balance based on literature data (non-traditional methods of diagnosis and therapy / edited Issueswe. - Kiev: Health, 1994. - 142 C.). The exposure time per one BAHT: when sedation is 30 seconds, while toning - 10 seconds. In the course of 10-12 daily procedures.
After further examination and selection magnetic effects carry out comprehensive treatment, including in addition to standard medical therapy: taking antidepressant azafena dose of 50 or 75 mg per day for 30 days; holding 1 per day in a single session course of 10-12 procedures magnetothermopower wavelength of 1.3 μm in the modulated mode, a frequency of 2.4 Hz minidocumentary nozzle 50 MT 10-30 with one biologically active point, and if sympathicotonia consistently perform sedation point GI 4 and toning points E 25 E 36, 6 MS; if vagotonia consistently tone up the point GI 4 and seatrout point E 25 E 36, MS.
For laserpuncture used vehicles physiotherapy laser exposure, for example, LTA "Moth-reflex".
Conducted examination and treatment by the proposed method, the analysis of relapses and remissions during the year in 28 patients On The P. The control group consisted of 20 patients treated by known standard method of treatment, comprising duspatalin at a dose of 200 mg 2 times a day for 2 weeks. The results are presented in table 1.
|Analysis of the results from this method of treatment (study group) compared with standard therapy (control group).|
|Index||The group of patients|
|The number of patients||28||20|
|The terms of relief of clinical symptoms (days)||2,3±0,4||4,6±0,8|
|Normalization contractility of the gallbladder (%)||90%||30%|
|Normalization of autonomic balance after treatment (%)||93%||7%|
|Restore daily chronoligical after treatment (%)||93%||7%|
|The lack of affective disorders||100%||25%|
|Relapse within one year (%)||0%||75%|
|Remission during the year (%)||100%||25%|
|The dynamics of quality of life on this method of treatment (study group) compared with standard therapy (control group)|
|Scale SF-36||Before the treatment||After the treatment|
|the main group||the control group|
|Physical functioning (PF)||68,2±6,4||96,0±14,2*||65,7±7,0|
|Physically-role functioning (RP)||54,1±5,6||90,0±13,8*||52,1±8,9|
|Physical pain (BP)||69,3±6,7||of 89.7±13,1*||58,3±9,7|
|General health (GH)||39,2±3,8*||73,2±11,6*||44,2±5,4|
|Vitality (VT)||54,9±5,2||62,2±9,2||of 58.9±6,0|
|Social functioning (SF)||61,1±7,1||85,0±12,8||68,2±6,3|
|Emotional role functioning. (RE)||63,3±6,0||65,0±10,0||64,5±6,1|
|Mental health (MH)||63,3±9,5||82,3±7,8||70,8±3,9|
Example 1. Patient B., 24, went to the polyclinic at the place of residence to the doctor-gastroenterologist 3.04.2009, with complaints of pain in the right hypochondrium, shooting character, radiating under the right shoulder that occurs after eating that occurs periodically, lasting at least six months with breaks.
Survey data: General analysis of blood, urine - without a pathology. EGD - without a pathology. Ultrasound of the gastrointestinal tract, gall bladder irregular shape.
Weg is consultative balance, including the daily monitoring of heart rate variability: RMSSD=11,4, LF/HF=6,4, testified sympathicotonia. Daily chronobiotic - offset acrophase, a decrease in the amplitude and mesara.
Data test questionnaires: HARS=15,8, HDRS=19,3. Quality of life (according to the questionnaire SF-36) is reduced by 1, 3, 4, 7, 8 scales.
Ultrasound ha with options. the breakdown. Conclusion - the signs of gallbladder dyskinesia in hypermotor type
The diagnosis of dyskinesia of the gallbladder on hypermotor type.
The patient received standard therapy duspatalin, and 1 time a day for 30 days azafen dose of 50 mg per day and magnetothermopower wavelength of 1.3 μm in the modulated mode, a frequency of 2.4 Hz minidocumentary nozzle 50 MT: sedation point GI 4 (30), toning (10) points E 25 E 36, 6 MS according to HRV about sympathicotonia) for 10 days.
Survey data after treatment. Clinical symptoms disappeared on the 3rd day.
Autonomic balance: RMSSD=26,2, LH/HF=1,5 (indicating that normotone); daily chronobiotic - normalization.
Data test questionnaires: HARS=3,8, HDRS=6,2. Quality of life according to the questionnaire SF-36 improved in all 8 scales.
Ultrasound ha with options. the breakdown. Conclusion - the contractile function of the gallbladder within the physiological norm.
During the year surveillance of recurrence was not.
Example 2. Patient K., 31, went to the polyclinic at the place of residence to the doctor-gastroenterolo is the 22.01.2009, with complaints of pain in the right hypochondrium, stabbing character, associated with food intake that occur periodically over 1.5 years.
Survey data: General analysis of blood, urine - without a pathology. EGD - without a pathology. Ultrasound of the gastrointestinal tract, gall - bladder with the bend in the neck.
Autonomic balance, including the daily monitoring of heart rate variability: RMSSD=12,1, LF/HF=5,8, testified sympathicotonia. Daily chronobiotic - offset acrophase, a decrease in the amplitude and mesara.
Data test questionnaires: HARS=15,2, HDRS=19,8. Quality of life (according to the questionnaire SF-36) is reduced by 1-4 and 8 scales.
Ultrasound ha with options. the breakdown. Conclusion - the signs of gallbladder dyskinesia in hypermotor type.
The diagnosis of dyskinesia of the gallbladder on hypermotor type.
The patient received standard therapy (duspatalin),
Survey data after treatment. Clinical symptoms disappeared on the 5th day.
Autonomic balance: RMSSD=12,6, LH/HF=5,6 (testified sympathicotonia); daily chronobiotic is unchanged.
Data test questionnaires: HARS=14,8, HDRS=18,6. Quality of life according to the questionnaire SF-36 is unchanged.
Ultrasound ha with options. the breakdown. Conclusion - the signs of gallbladder dyskinesia in hypermotor type.
After 3 months, the patient relapsed.
Thus, the application of the proposed method for the correction obiazatelen systems of the body, in particular, mental status, autonomic balance, daily chronobiotics, accompanied by persistent normalization contractility ha, promotes edema clinical manifestations of the disease, lengthen remission, reducing the frequency of relapses, improve the quality of life of patients during treatment, JP.
The way to improve the quality of life and treatment of patients with dyskinesia of the gallbladder, including medication, characterized in that additionally taking into account the severity of anxiety and depressive disorders according to the scale of Hamilton to assess anxiety HARS and scale of Hamilton, to assess depression HDRS prescribed antidepressant azafen when clinically defined disorders in a dose in the dose of 75 mg per day, expressed in subclinical affective disorders in a dose of 50 mg per day for 30 days and taking into account individual peculiarities of vegetative balance are magnetothermopower wavelength of 1.3 μm in the modulated mode, a frequency of 2.4 Hz minidocumentary nozzle 50 MT 10-30 with one biologically active point for 10-12 procedures; and in the case of sympathicotonia seatrout point GI 4 and tone tocha E 25 E 36, 6 MS; if vagotonia tone up the point GI 4 and seatrout point E 25 E 36, 6 MS.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical industry and medicine. Claimed is application of N-carbamoyl-4-(n-methoxyphenyl)-2-pyrrolidone of structural formula as means possessing antidepressive, anxiolytic and nootropic action. This low-toxic compound (LD50 2263.88 mg/kg) possesses high antidepressive, anxiolytic and nootropic activity, affect of which is not accompanied by hypnosedative phenomena, or reduction of mental and physical work ability.
EFFECT: demonstrated is antidepressive and anxiolytic action of compound already in its single application, which makes the medication different from most known antidepressants, requiring at least one-week long intake to develop their effect.
SUBSTANCE: invention relates to compounds of formula , where X denotes S; R1 and R2 taken together with atoms to which they are bonded form a 5-member carbocycle, substituted with up to two substitutes selected from alkyl and CF3; R3 is selected from a group consisting of a hydrogen atom and C1-8-alkyl; R3a denotes a hydrogen atom; R4 denotes a hydrogen atom; R4a denotes a hydrogen atom; R5 denotes a hydrogen atom; R5a denotes a hydrogen atom; R6 denotes a hydrogen atom; R6a denotes a hydrogen atom; R7 denotes a hydrogen atom; or pharmaceutically acceptable salts thereof. The invention also relates to compounds of the given formula, compounds selected from the group, as well as a pharmaceutical composition.
EFFECT: obtaining novel biologically active compounds which modulate serotonin receptor activity.
6 cl, 19 ex, 1 tbl
SUBSTANCE: invention relates to novel cyclohexylamine derivatives of formula (I), having inhibiting properties towards at least one monoamine transporter, such as serotonin transporter, dopamine transporter or norepinephrine transporter, or a combination of two or more transporters. The compounds can be used to treat and/or prevent central nervous system disorders such as pain, depression, anxiety, schizophrenia, sleep disorder etc. In formula (I) , n equals 0 or 1; s equals 1, 2 or 3, m equals a whole number from 0 to 12; Ar is
or where Y and Z are (i) both halogen; or (ii) one of Y and Z is CF3 or OCF3 and the other is hydrogen; Y1, Z1, Y2 and Z2 each independently denotes H or a halogen; each X independently denotes H, halogen, CF3, OR5, (C1-C4)alkyl, optionally substituted with halogen or OH, or NR6R7; each R1 and R2 independently denotes H or (C1-C6)alkyl; and each R3 and R4 independently denotes H or (C1-C9)alkyl optionally substituted with OH; where each R5 independently denotes H, (C1-C4)alkyl or phenyl; and each R6 and R7 independently denotes H or (C1-C4)alkyl; where at least two of R1, R2, R3, R4 and X together with atoms to which they are bonded are optionally bonded to form a 5-6-member ring, where the 5-6-member ring is selected from: a) R3 and R4 together with a nitrogen atom to which they are bonded optionally form a pyrrolidine, piperidine, piperazine or morpholine ring, which is optionally substituted with (C1-C4)alkyl; b) when R3 is H or lower alkyl, X and R4 together with atoms to which they are bonded optionally form a 1,3-oxazine ring; c) two X substitutes together with a carbon atom to which they are bonded optionally form a 1,3-dioxolane ring; and d) when R1 and R3 denote hydrogen, R2 and R4 together with atoms to which they are bonded optionally form a 5- or 6-member saturated heterocyclic ring containing one nitrogen atom.
EFFECT: high efficiency of using the compounds.
29 cl, 36 dwg, 11 tbl, 6 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed are dietary and/or nutriceutic pharmaceutical composition for peroral application which contains S-adenosylmethi-onine-para-toluolsulfonate (SAMe) in combination with inositol and/or ino-sitol-1-phosphate and pharmaceutically acceptable excipients, in which at least one of and pharmaceutically acceptable excipients represents magnesium oxide in concentration from approximately 1.0 to approximately 10.0% of composition weight (versions), method of its obtaining, method of stabilisation of hard food and/or nutriceutic pharmaceutical composition based on SAMe-para-toluolsulfonate by application of inositol and/or inositol-1-phosphate, application of SAMe-para-toluolsulfonate in combination with inositol and/or inositol-1-phosphate for obtaining composition for treatment of depressive states and panic syndromes.
EFFECT: inclusion of magnesium oxide into composition increases SAMe-para-toluolsulfonate stability, inositol reduces SAMe-para-toluolsulfonate hygroscopicity and contributes to its soothing and antidepressant action.
27 cl, 41 tbl, 7 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical industry, in particular to medications for treatment of depression. Traditional Chinese medication for treatment of depression. Method of preparing traditional Chinese medication for treatment of depression. Product. Pharmaceutical composition for treatment of depression. Method of preparing pharmaceutical composition (versions). Application of traditional Chinese medication in production of medications for treatment of depression. Application of product for production of medication for treatment of depression. Method of depression treatment (versions).
EFFECT: medications are efficient for treatment of depression.
21 cl, 14 tbl, 7 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to 2,8-dimethyl-5-[2-(6-methyl-pyridyl-3)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole salts of general formula (1) exhibiting antidepressive and antihypoxic activity where n=1, 2 Y = (CH2COOH)2, HOOCCH(OH)CH2COOH, (HOOCCH2)2C(OH)COOH. Besides, the invention concerns a pharmaceutical agent.
EFFECT: ensured production of new biologically active compounds exhibiting antidepressive and antihypoxic activity.
6 cl, 5 ex, 2 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine, namely to pharmacology, and can be used for treatment of depression-like disorders in experiment. For this purpose intraperitoneally introduced is 3-metoxythietan-1,1-dioxide or 3-(2-isoproxy-5-methyl phenoxy)thietan-1,1-dioxide or 3-phenylsulfonylthietan-1,1-dioxide one time in dose 2 or 20 mg/kg, or daily during two weeks in dose 2 mg/kg.
EFFECT: invention extends arsenal of efficient and safe medicatuions, used for correction of depressive disorders.
3 tbl, 2 ex
SUBSTANCE: invention relates to novel substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidine-2,6-diamines of general formula 1, their pharmaceutically acceptable salts and/or hydrates which have serotonin 5-HT6 receptor antagonist properties and can be used in treating or preventing development of various central nervous system diseases, whose pathogenesis is associated with 5-HT6 receptors, particularly Alzheimer's disease, Parkinson's disease, Huntington disease, schizophrenia, other neurodegenerative diseases, cognitive and anxiety disorders and obesity. In general formula (I): R1, R2 and R4, which are optionally identical, independently denote C1-C3 alkyl; R3 and R4, which are optionally identical, denote: a hydrogen atom, optionally substituted C1-C3 alkyl or acetyl; R5 denotes a hydrogen atom or halogen atom.
EFFECT: high treatment efficiency.
13 cl, 12 dwg, 4 tbl, 12 ex
SUBSTANCE: compound is ((S)-1-phenyl-propyl)-amide 3-(methane sulphonyl amino)-2-phenyl- quinoline-4-carboxylic acid, stereoisomer, enantiomer or pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition based on the disclosed compound.
EFFECT: novel derivative of methyl sulphonamide quinoline which can be used to modulate the NK-3 receptor.
2 cl, 10 ex
SUBSTANCE: invention relates to novel compounds of formula I in which A denotes X denotes O; R denotes H; R1 denotes OH, CN, a nitro group, NH2, NR2CSR8, NR2CONR2R9, NR2C SNR2R9, NR2SO2R10, NR2CONR6R7, NR2CSNR6R7, NR2R9, SO2R10, SOR10, alkyl containing 1-4 carbon atoms, fluorinated alkyl containing 1-4 carbon atoms, alkenyl containing 2-6 carbon atoms, alkynyl containing 2-6 carbon atoms, where each alkyl, fluorinated alkyl, alkenyl or alkynyl group in each case is unsubstituted or substituted with Ar or He, cycloalkenyl containing 5-8 carbon atoms, alkoxy group containing 1-4 carbon atoms, cycloalkoxy group containing 3-7 carbon atoms, cycloalkylalkoxy group containing 4-7 carbon atoms, fluorinated alkoxy group containing 1-4 carbon atoms, fluorinated hydroxyalkyl containing 1-4 carbon atoms, hydroxyalkoxy group containing 2-4 carbon atoms, an ordinary hydroxyalkoxy group containing 2-4 carbon atoms, monoalkylamino group containing 1-4 carbon atoms, dialkylamine group, where each alkyl group independently contains 1-4 carbon atoms, alkoxycarbonyl containing 2-6 carbon atoms, Het or OAr; R2 denotes H, alkyl containing 1-4 carbon atom, cycloalkyl containing 3-7 carbon atoms, and cycloalkyl alkyl containing 4-7 carbon atoms; R6 and R7 independently denote H, alkyl containing 1-4 carbon atoms, cycloalkyl containing 3-7 carbon atoms, or cycloalkylalkyl containing 4-7 carbon atoms, or R6 and R7 together denote an alkylene group containing 4-6 carbon atoms, which forms a ring with an N atom; R8 denotes alkyl containing 1-4 carbon atoms, fluorinated alkyl containing 1-4 carbon atoms, alkenyl containing 3-6 carbon atoms, alkynyl containing 3-6 carbon atoms, where each alkyl, fluorinated alkyl, alkenyl or alkynyl group is unsubstituted or substituted with Ar, cycloalkyl containing 3-7 carbon atoms, or Het; R9 denotes Ar or Het; R10 denotes alkyl containing 1-4 carbon atoms which is unsubstituted or substituted with Ar, or NR6R7; Ar denotes an aryl group containing 6-10 carbon atoms, which is unsubstituted or substituted once or several times with an alkyl containing 1-8 carbon atoms, alkoxy group containing 1-8 carbon atoms, halogen, cyano group or combinations thereof; and Het denotes dihydropyranyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, isoxazolinyl, thiazolyl, oxazolyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidinyl, indolyl, quinolinyl, isoquinolinyl or naphthyridinyl, which is unsubstituted or substituted once or several times with halogen, aryl containing 6-10 carbon atoms, which is optionally substituted with alkyl containing 1-8 carbon atoms, alkoxy group containing 1-8 carbon atoms, oxo group, -CXR11 or combinations thereof, or R11 denotes alkyl containing 1-4 carbon atoms which is unsubstituted or substituted with Ar or Het; or pharmaceutically acceptable salts thereof, where formula IA is attached to the rest of the bonding molecule in the 3, 4 or 7 positions. The invention also relates to a pharmaceutical composition and to use of compounds in any of claims 1-37.
EFFECT: obtaining novel biologically active compounds, having nicotinic acetylcholine receptor subtype α7 ligand activity.
59 cl, 316 ex
SUBSTANCE: invention relates to medicine, namely to ophthalmology, physiotherapy, and can be used in treatment of blepharoconjunctivitis, induced by Demodex mites. Method includes instillation of trophic drops and further physiotherapeutic impact during 5.0-10.0 minutes. Impact is realised by pulse irradiation with wavelength 800-1200 nm, continuous irradiation with wavelength 630-670 nm and magnetic field with intensity H=20-45 mT. Pulse irradiation is carried out with average power Pav pul =3.0-10.0 mW, pulse power Ppul=2.0-4.0 W and with sweep frequency of pulse repetition fpul. from 5.0 Hz to 10.0 kHz. Continuous irradiation is performed with average irradiation power Pav cont to 50.0 mW. Impact by electromagnetic irradiation and magnetic field is performed on eyelids and areas adjacent to eye. Treatment course consists of 8-10 sessions.
EFFECT: method reduces treatment terms and increases its efficiency due to suppression of mite vital functions by electromagnetic field irradiation.
SUBSTANCE: invention relates to medicine, namely to psychiatry and physiotherapy, and can be used for treatment of low-intensive laser therapy of neurotic disorders. For this purpose carried out is irradiation of blood by helium-neon laser with wavelength 0.63 mcm and power 1-2 mW during 5-10 minutes intravenously or over vein onto vascular fascicle in the area of elbow bend on the left. After that carried out is multiple combined cutaneous impact on paired anatomical-functional zones and neurovascular bundles and successive on organ projections. Cutaneous contact impact during each zone processing is performed simultaneously by two types of irradiations: continuous red with wavelength 0.64 mcm and power 20 mW/imp and pulse infrared with wavelength 0.89 mcm, power 4.5-5 W in successively increasing mode in frequency range from 80 to 1500 Hz during session with time of irradiation by each frequency 8-45 seconds per zone.
EFFECT: method ensures efficient treatment of neurotic disorders of various genesis in period of exacerbation and prevention of exacerbations due to recovery of sanogenic adaptive responses of organism and personal response, recovery of ability for self-regulation and adaptation to various psychogenies, more favourable course of rehabilitation period, as well as reduction of drug load on patient.
7 cl, 4 tbl, 2 ex
SUBSTANCE: invention relates to field of veterinary. In hypotrophic calves puncture of jugular vein is performed with needle which has light guide in it. Light guide is switched to laser irradiating head for intravenous blood irradiation with wavelength 0.63 mcm and power 1.5 mW. Procedure is carried out during 5 minutes one time per day, with one-day interval, five times.
EFFECT: application of method increases natural resistance of hypotrophic calves efficiently and in a safe way.
7 dwg, 1 ex
SUBSTANCE: invention relates to medicine, ophthalmology, and can be used for slowing down proliferation processes in injured retina. For this purpose not less than 2 mg of alasens are introduced into sub-Tenon space. Then, after 1.5-2 hours impact by laser irradiation with wavelength 632.8 nm, power density 47.7-55.7 mW/cm2 is performed during 10-14 minutes. 12-14 after impact anti-oxidant therapy is carried out for not less than 10 days.
EFFECT: method makes it possible to ensure adequate slowing down proliferation due to inhibition of angiogenesis in zones of proliferating cells by use of more aggressive parameters of laser impact with simultaneous prevention of preretinal fibrosis development due to protective action onto irradiated tissues; simplify treatment methods due to elimination of per oral administration of prophotosensitiser.
11 dwg, 2 ex
SUBSTANCE: invention relates to medicine, photodynamic therapy of tumours. Photosensitiser (PS), in particular radachlorine is added to nanoparticles of emulsion of perfluorocarbons (PFC), consisting of perfluorodecalin and perfluoromethylcyclohexylpiperidine, stabilised with proxanol 268 solution. Emulsion of PFC with PS is added to stem cells of bone marrow (SCBM), in particular, autologic. Their joined cultivation is carried out, after which SCBM is introduced to subject with malignant tumour, in particular breast tumour. Zone of tumour growth is subjected to impact by light irradiation in dose sufficient for complete or partial tumour destruction. Subject can be represented by a mammal, in particular, human being.
EFFECT: method ensures targeted impact, complete or partial tumour regress, excludes systemic phototoxic injuries.
6 cl, 3 ex, 3 dwg
SUBSTANCE: invention refers to medicine, namely gastroenterology, and can be used for treating chronic cholecystitis. For this purpose, with underlying the drug-induced therapy in the patients with diagnosed anxiodepressive disorder, the antidepressant azaphen is administered for 30 days. Clinically evident mood disorders require the dosage 25 mg 3 times a day, while in subclinically evident mood disorders, the dosage is 25 mg 2 times a day; it is combined with transcutaneous magnetic-laser therapy by wave length 0.89 mcm, with a magnetic cap 150 mT for 2 min with covering a solar plexus on a projection of a gall bladder and to a projection of a duodenum: if observing evident pain syndrome of frequency 820 Hz followed by gradual frequency reduction with remitting clinical manifestations of the disease to 80 Hz; mild pain syndrome of frequency 360 Hz followed by gradual frequency reduction with remitting clinical manifestations of the disease to 80 Hz; In the absence of pain syndrome of frequency 80 Hz.
EFFECT: method allows reducing a degree of manifestation of pain syndrome, prolonging remission, reducing frequency of recurrences due to normalised daily chronobiorhythm, vegetative balance, corrected mood disorders.
1 ex, 2 tbl
SUBSTANCE: invention refers to medicine, particularly ophthalmology, and concerns conservative treatment of pterygium. The preparation Alasens 15 mg/kg of weight is orally introduced in a patient. In 3 hours after introduction of the preparation, a pterygium area is once exposed to laser at wave length 635 nm at total power density 80-100 J/cm2. The exposure is continued to reduce intensity of the induced pterygium area to a level or lower than surrounding bulbar conjunctiva.
EFFECT: method provides effective conservative treatment of the disease, stabilising growth and promoting pterygium tissue regression, including due to obliteration of new vessels, while preserving eyeball tissues surrounding pterygium that allows avoiding surgical management of the disease.
1 ex, 2 dwg
SUBSTANCE: invention refers to medicine, and can be used for surgical management of nodular and multinodular nontoxic goiter. For this purpose, at the first stage a thyroid gland is punctured with a puncture needle G19. The needle is moved to the centre of the goiter from the mid-line of an anterior surface of neck with ultrasonic guidance. Then 0.35% radachlorine 1 ml per 1 cm3 is injected. Then the needle is removed. At the second stage, 5-10 minutes later needle puncture is performed again, and a light guide is introduced through needle opening. It is followed by laser exposure at wave length 0.662 mcm, power 100 to 900 mWt for 11-20 minutes. If observing the presence of more than one palpable abnormality in the same lobe at the first and second stages, the needle introduced earlier is alternately moved in the centre of the following goiter, and similarly all the procedures are repeated for required number of times.
EFFECT: method ensures evident and permanent clinical effect with no thyroid tissue destruction with minimum tissue injures, provides achieving gradual regress of pathological process in tissues and its replacements by normal thyroid epithelium with no destructive changes, reducing risk of specific postoperative complication in the form of bleeding.
SUBSTANCE: invention refers to medicine, namely to oncology, also can be used in treating patients with solid tumours. For this purpose, 1-2 days prior to the initiation of chemotherapeutic procedures, a preparation of marrow mesenchymal stem cells coated with perfluorocarbon nanoparticles produced by incubation in a medium containing a pharmaceutically acceptable aqueous perfluorocarbon nanoemulsion of a particle diameter 300 nm and less is introduced to a patient intravenously in dose 0.5-10·106 cell/kg. Then the chemotherapeutic procedures follow with underlying oxygenated gas mixture inhalations at normal or high pressure.
EFFECT: method provides effective growth inhibition and reduced tumour size, including ensured by increasing tumour cell sensitivity to chemopreparations.
9 cl, 4 ex
SUBSTANCE: invention refers to medical equipment, namely devices for temperature control of skin surface and biotissue subcutis. The device comprises a laser emitter, a working chamber and a gas system, a fluid tank and temperature regulation system, a mixing chamber, a fluid injection system into the mixing chamber, fluid supply channels into the injection system, a suction system, withdrawal channels for gas and fluid pumped-out by the suction system from the working chamber. A gas flow is supplied into the mixing chamber from the gas system for atomisation and formation of a gas-drop mixture supplied into the working chamber. On top, the chamber is formed by an optical window transparent for working radiation in a laser pathway, by a skin surface at the bottom and by walls on each side. A gap thickness between an internal surface of the optical window and a skin surface is d≥4 λ\α, while fluid temperature in the chamber is specified as Tf≥Tsur[1+λe/(αδe)]-[λe/(αδe)]T0, where λe, δe are a heat conduction coefficient and a skin surface thickness respectively, α is a skin surface thermal conductivity coefficient, T0 is initial skin surface temperature, Tsur is required skin surface temperature. Gas temperature in the working chamber is 5-20°C higher than fluid temperature. The fluid is skin neutral and has a boiling point exceeding body temperature.
EFFECT: use of the invention enables more efficient and uniform cooling of a skin surface area and improving result stability of temperature control of a skin surface.
2 cl, 2 dwg
SUBSTANCE: method involves dietotherapy that is M.I. Pevzner's diet No. 5, therapeutic exercises and oral administration of the preparation Enterosan. Enterosan is dosed one capsule 5 times a day after meals for 2-3 weeks. The administration is combined with general magnetotherapy. That is ensured by exposure to low-frequency traveling pulse magnetic field of frequency 100 Hz and magnetic induction gradually increasing within 10 % to 80 % from the maximum value 3.5 mT. The magnetic field is directed forward - backward - forward. Exposure time is 20-25 minutes. 4-5 procedures are performed every week. The therapeutic course is 8-10 procedures.
EFFECT: method provides intensification of general and hepatic haemodynamics, improvement of bile production and secretion processes, elimination of inflammatory process, normalisation of a gastric and pancreatic secretory function, correction of motor-evacuation and microbiotic intestinal disorders, lower lipid peroxidation activity and stimulation of antioxidant system activity.